Rethinking cardiac neurodevelopment: a dimensional model of adversity in congenital heart disease

Adam R Cassidy1

  • 1Departments of Psychiatry & Psychology and Pediatric & Adolescent Medicine, Mayo Clinic, Rochester, MN, United States.

Frontiers in Pediatrics
|August 15, 2026
PubMed

Insights

Children with congenital heart disease (CHD) face unexplained neurodevelopmental (ND) challenges. A new dimensional model links brain vulnerability and environmental adversity (deprivation/threat) to predict ND outcomes, improving targeted interventions.

Area of Science:

  • Neuroscience
  • Developmental Psychology
  • Pediatric Cardiology

Background:

  • Neurodevelopmental (ND) outcomes in children with congenital heart disease (CHD) show limited improvement and unexplained variability.
  • Current models inadequately explain how environmental factors influence neurobehavioral development in CHD.
  • Predicting individual developmental trajectories for children with CHD remains challenging.

Purpose of the Study:

  • To propose an integrated dimensional model for understanding neurodevelopmental outcomes in children with CHD.
  • To explain the heterogeneity in ND outcomes by considering CHD-related brain vulnerability and environmental adversity.
  • To provide a mechanistic framework for improved developmental surveillance and interventions.

Main Methods:

  • Conceptualizing ND outcomes through an integrated dimensional model.
  • Integrating CHD-related brain vulnerability (prenatal dysmaturation, perioperative injury, altered brain structure) with environmental adversity (deprivation, threat).
  • Drawing from the Dimensional Model of Adversity and Psychopathology.

Main Results:

  • The proposed model conceptualizes ND outcomes as arising from independent and interactive effects of brain vulnerability and environmental adversity.
  • Deprivation-related exposures are predicted to affect cognitive, language, and executive functions.
  • Threat-related exposures are predicted to influence emotional learning, stress regulation, and psychopathology risk.

Conclusions:

  • The dimensional model offers a mechanistic account of ND heterogeneity in CHD.
  • This framework generates testable hypotheses regarding developmental trajectories in children with CHD.
  • It supports more precise developmental surveillance and targeted intervention strategies for improved neurodevelopmental outcomes.

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Attention-Deficit/Hyperactivity Disorder01:30

Attention-Deficit/Hyperactivity Disorder

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.